Clinical Markers of Panic and Generalized Anxiety Disorder

Generalized Anxiety Disorder and Panic Disorder: Differences in Clinical Manifestation and Prognosis, a Multicenter Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06071819

Enrollment

290

Registered

2023-10-10

Start date

2022-08-01

Completion date

2022-10-31

Last updated

2023-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duration of Untreated Illness, Generalized Anxiety Disorder, Panic Disorder

Brief summary

The goal of this observational study is to compare socio-demographic and clinical features in patients affected by Generalized Anxiety Disorder (GAD) and by Panic Disorder (PD). The main questions it aims to answer are: * which socio-demographic/clinical markers are associated to GAD or PD diagnosis? * which factors are associated with a longer duration of untreated illness (DUI) in GAD and in PD? Participants will signed a written informed consent and socio-demographic/clinical variables will be retrospectively collected. Researchers will compare GAD and PD groups in terms of socio-demographic and clinical features, including DUI, to better characterize the two disorders and to investigate factors associated to a longer DUI.

Interventions

DIAGNOSTIC_TESTStructured Clinical Interview for DSM-5

A structured interview will be administered to confirm the diagnosis reported in clinical charts

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* age 18-65 years; * ability and willing to give informed consent; * fluency in Italian language; * diagnosis of GAD or PD according to the criteria of the Diagnostic and Statistical Manual of Mental Disorder, 5th edition.

Exclusion criteria

* intellectual disability; * lack of clinical and socio-demographic information; * patients treated for less than three months in the outpatient clinics for the impossibility of a comprehensive collection of clinical variables.

Design outcomes

Primary

Measure	Time frame	Description
Dichotomous socio-demographic / clinical variables	Three months	Multiple family history of psychiatric disorders (yes/no), pre- and post-onset psychiatric poly-comorbidities (yes/no), presence of personality disorder (yes/no), pre- and post-onset poly-substance misuse (yes/no), pre- and post-onset medical poly-comorbidities (yes/no), suicide attempts (yes/no), hospitalizations (yes/no), poly-therapy (yes/no), presence of poly-side effects (yes/no), presence of lifetime psychotherapy (yes/no)
Quantitative socio-demographic / clinical variables	Three months	Age (years), age at onset (years), duration of illness (years), duration of treatment (years)
Sex	Three months	Sex (male/female)
Occupation	Three months	Occupation (employed/unemployed)
Pre-/post-onset Comorbidity	Three months	Psychiatric and medical comorbidity
Substance misuse	Three months	Substance misuse
Treatment	Three months	Treatment, treatment discontinuation and side effects

Secondary

Measure	Time frame	Description
Duration of untreated illness (DUI) in months = time between the onset of PD and the first appropriate pharmacological treatment.	Three months	Factors associated to DUI among GAD and PD groups. Information about DUI have been registered according to what the patient reported (clinical records and structured interviews)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026